Drug intelligence / Profile preview

sodium polysulthionate

Development stage: Phase 2
Lead developer: Sulfagenix
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

Sodium polysulthionate is a drug candidate initially developed by Sulfagenix for cardiovascular diseases. It is distinct from sodium polystyrene sulfonate and sodium polysulfide, both of which are unrelated substances with different chemical properties and uses. Sodium polysulthionate has reached Phase 1/2 in clinical development, but detailed information about its mechanism of action, molecular structure, or specific indications within cardiovascular disease remains limited in the public domain[4].

Brand names: SG1002SG-1002SG 1002
Other names: sodium polysulthionatehydrogen sulfide donorH2S prodrugH-2S prodrugH 2S prodrug

Targets

CBS (Cystathionine beta-synthase)

Beyond the preview

Go deeper on sodium polysulthionate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium polysulthionate.

Explore the full profile